• We specialize in small molecule inhibitors, agonists, antagonists and screening libraries!
Search Site
Home >> Signaling Pathways >> Tyrosine Kinase >> PDGFR >> Sorafenib Tosylate
Related Products
Sorafenib TosylateRaf kinases and tyrosine kinases inhibitor

Sorafenib Tosylate

Catalog No. A8245
Size Price Stock Qty
10mM (in 1mL DMSO) $55.00 In stock
20mg $105.00 In stock
50mg $190.00 In stock
200mg $470.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

Sorafenib Tosylate

Related Biological Data

Sorafenib Tosylate
The number of nuclei breaking the internal limiting membrane (ILM). A: Controlled group; B: ROP group; C: Vehicle-treated ROP group; D: Low doses sorafenib-treated ROP group; E: Middle doses sorafenib-treated ROP group; F: High dose sorafenib-treated ROP group. Arrows: lumen. aP<0.05.

Related Biological Data

Sorafenib Tosylate

Related Biological Data

Sorafenib Tosylate

Biological Activity

Description Sorafenib Tosylate (Bay 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.
Targets Raf-1 B-Raf VEGFR2 PDGFRβ    
IC50 6 nM 22 nM 90 nM 57 nM    

Sorafenib Tosylate Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


Sorafenib Tosylate Molarity Calculator



Chemical Properties

Cas No. 475207-59-1 SDF Download SDF
Chemical Name 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide;4-methylbenzenesulfonic acid
Canonical SMILES CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Formula C21H16ClF3N4O3.C7H8O3S M.Wt 637.03
Solubility >31.9mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request


Sorafenib tosylate, also named nexavar, is a small-molecule anticancer compound [1]. It is also a novel oral Raf kinase and a vascular endothelial growth factor receptor (VEGFR) inhibitor. It inhibits tumor cell proliferation and tumor angiogenesis [2]. To HepG2 cells (1× 106), the IC50 of sorafenib tosylate is 2.09μg/ml [3].  
Raf is a mitogen-stimulated protein kinase that functions as a component of the signaling cascade that leads to the stimulation of mitogen-activated protein kinase [4].
Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular endothelial cells [5].
Treatment with nexavar potently inhibited the cell proliferation of MV4-11 cells (FLT3-ITD) in a dose-dependent manner with an IC50 of 0.88 nM. In MV4-11 cells, sorafenib tosylate of a concentration of 100 nM induced 43.6±5.2% of the cells to undergo apoptosis whereas in EOL-1 cells a concentration as low as 10 nM induced 89.29±1.8% of the cells to be apoptotic [6].
Nude rats at the age of 6 weeks injected with 105 MDA-MB-231 cells were involved. After monotherapy with sorafenib tosylate a significant reduction of the osteolytic lesion volume was observed on days 45 and 55 and of the soft tissue component volume on day 55 in comparison to untreated animals (p < 0.05). Compared to controls, treatment with sorafenib tosylate made bone metastases show significantly decreased values of Amplitude A and kep from day 35 to 55 (Amplitude A: p<0.01; kep p<0.01 on days 35 and 55; p<0.05 on day 45) [7].
[1]. Chetan Lathia, John Lettieri, Frank Cihon, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol, 2006, 57: 685-692.
[2]. M. J. Gnoth, S. Sandmann, K. Engel, et al. In Vitro to In Vivo Comparison of the Substrate Characteristics of Sorafenib Tosylate toward P-Glycoprotein. Drug Metabolism & Disposition, 2010, 38: 1341–1346.
[3]. Sayantan Dey, Subhadeep Roy, Nilanjana Deb, et al. Anti-carcinogenic Activity of Ruellia Tuberosa L. (Acanthaceae) Leaf Extract on Hepatoma Cell Line & Increased Superoxide Dismutase Activity on Macrophage Cell Lysate. Int J Pharm Pharm Sci, 2010, 5(Suppl 3): 854-861.
[4]. Markus Wartmann and Roger J. Davis. The Native Structure of the Activated Raf Protein Kinase Is a Membrane-bound Multi-subunit Complex. The Journal of Biological Chemistry, 1994, 269(9): 6695-6701.
[5]. Gera Neufeld, Tzafra Cohen, Stela Gengrinovitch, et al. Vascular endothelial growth factor (VEGF) and its receptors. The FASEB Journal, 1999, 13: 9-22.
[6]. D Auclair, D Miller, V Yatsula, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia, 2007, 21:439-445.
[7]. Maximilian Merz, Dorde Komljenovic, Stefan Zwick, et al. Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. European Journal of Cancer, 2011, 47:277-286.